{"id":1010172,"date":"2026-10-14T11:25:35","date_gmt":"2026-10-14T15:25:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/"},"modified":"2026-10-14T11:25:35","modified_gmt":"2026-10-14T15:25:35","slug":"qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/","title":{"rendered":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications"},"content":{"rendered":"

<\/p>\n

Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications<\/b><\/p>\n

Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that L\u014dkahi believes may become a source of long-term value to patients and manufacturers <\/i><\/p>\n

RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–
\nL\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the public launch of Qare\u2122, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare\u2122 enables users to compare their self-reported results, side effects, and out-of-pocket costs against people with a similar profile, whether they take the same medication or a different one in the class. Cohort comparisons are presented in aggregate, and Qare\u2019s data infrastructure is hosted by third-party providers that maintain SOC 2 and ISO 27001 certifications.<\/p>\n

\nQare\u2122 is built around a direct question that traditional tracking tools do not answer: \u201cHow do the results of my medication experience compare with people like me?\u201d By placing each user\u2019s results in the context of a matched cohort, Qare turns individual records into comparative insight.<\/p>\n

\n\u201cHealthcare data is a big business that many times misses in delivering actionable value for patients, providers and manufacturers. L\u014dkahi looks to address that,\u201d said Erik Emerson, Chief Executive Officer of L\u014dkahi Therapeutics\u2122. \u201cWe believe Qare\u2122 has the potential to give patients additional context for conversations with their healthcare providers, offer providers insight into results by cohort and provide manufacturers a valuable vehicle to improve patient marketing and differentiation.\u201d<\/p>\n

\n\u201cPeople on GLP-1s and many other medications have tools to record their experience, but very little context for what their results mean,\u201d said Anna Lewandowski, Director, ai\u00b2 Division. \u201cQare is designed to provide that context. As more people join, we expect each cohort to become more specific, which we believe will make the platform more useful for its users and may enable a clearer, real-world view of how users experience treatments across the industry.\u201d<\/p>\n

\nQare\u2122 was developed through ai\u00b2 Accelerator\u2122, an extension of L\u014dkahi\u2019s ai\u00b2 platform and university partnerships which is focused on leveraging technology to improve healthcare.<\/p>\n

\nThe initial launch focuses on GLP-1 medications. L\u014dkahi expects to add other therapeutic categories to Qare\u2122, via organic expansion and industry partnerships. As the user base grows, Qare is designed to generate an increasingly granular, de-identified real-world dataset, which L\u014dkahi believes may support future research and industry partnerships.<\/p>\n

Qare\u2122 is now publicly available. Visit qare-app.com to learn more.<\/b><\/p>\n

About L\u014dkahi Therapeutics\u2122<\/b><\/p>\n

\nL\u014dkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai\u00b2 platform and ai\u00b2 Futures Lab execution model, L\u014dkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com<\/a>. For more information about the ai\u00b2 Division program, please visit www.ai2equals.com<\/a>. Information on the company\u2019s websites does not constitute a part of and is not incorporated by reference into this press release.<\/p>\n

About Glucotrack, Inc.<\/b><\/p>\n

\nGlucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com<\/a>. Information on the company\u2019s website does not constitute a part of and is not incorporated by reference into this press release.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate,\u201d “believe,\u201d “expect,\u201d “plan,” \u201cintend,\u201d \u201cmay,\u201d \u201cpotential,\u201d \u201cdesigned to,\u201d and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to: the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise); risks relating to the development, launch, and market acceptance of the Qare\u2122 platform; the ability to achieve user adoption and engagement with Qare\u2122; the ability to generate revenue from Qare\u2122 or its data, including through industry partnerships; risks relating to data privacy, cybersecurity and the collection, de-identification and use of health information, and compliance with applicable laws and regulations; competition in the healthcare analytics and digital health markets; the ability to expand Qare\u2122 to additional therapeutic categories on the anticipated timeline; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026, and subsequent Quarterly Reports on Form 10-Q.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20261014530959\/en\/<\/a><\/span><\/p>\n

L\u014dkahi Therapeutics\u2122
\n<\/b>
ir@lokahithera.com<\/a><\/p>\n

KEYWORDS:<\/b> California New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Software Biotechnology Pharmaceutical Health Artificial Intelligence Health Technology Technology Apps\/Applications<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that L\u014dkahi believes may become a source of long-term value to patients and manufacturers RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the public launch of Qare\u2122, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare\u2122 enables users to compare their self-reported results, side effects, and out-of-pocket costs … <\/p>\n

Continue reading “Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010172","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nQare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that L\u014dkahi believes may become a source of long-term value to patients and manufacturers RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the public launch of Qare\u2122, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare\u2122 enables users to compare their self-reported results, side effects, and out-of-pocket costs … Continue reading "Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T15:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications\",\"datePublished\":\"2026-10-14T15:25:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/\"},\"wordCount\":1076,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/\",\"name\":\"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-10-14T15:25:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/","og_locale":"en_US","og_type":"article","og_title":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk","og_description":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that L\u014dkahi believes may become a source of long-term value to patients and manufacturers RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced the public launch of Qare\u2122, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare\u2122 enables users to compare their self-reported results, side effects, and out-of-pocket costs … Continue reading \"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-14T15:25:35+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications","datePublished":"2026-10-14T15:25:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/"},"wordCount":1076,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/","name":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-10-14T15:25:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20261014530959r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/qare-is-here-lokahi-therapeutics-launches-a-proprietary-new-way-to-compare-your-care-beginning-with-glp-1-medications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Qare\u2122 Is Here: L\u014dkahi Therapeutics\u2122 Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010172"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010172\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}